Introduction {#sec1-0300060519860951}
============

Frontotemporal dementia (FTD) is a neurodegenerative disorder that is characterized by neuronal loss in the frontal and temporal lobes.^[@bibr1-0300060519860951]^ Clinically, patients affected by FTD can be broadly divided into two main subtypes. One subtype is found in those with predominant behavioral and social comportment disorders (behavioral variant frontotemporal dementia \[bvFTD\]). The other subtype is found in those with primary language disturbances (primary progressive aphasia \[PPA\]), which includes semantic PPA (svPPA) and non-fluent/agrammatic PPA (naPPA).^[@bibr2-0300060519860951][@bibr3-0300060519860951][@bibr4-0300060519860951][@bibr5-0300060519860951]--[@bibr6-0300060519860951]^

FTD is neuropathologically characterized by aggregates of three different proteins in the frontal and temporal lobes, including tau, TAR DNA-binding protein 43, and fused-in-sarcoma protein.^[@bibr7-0300060519860951]^ FTD is inherited in approximately one third of cases and the most common pathogenic mutations have been found in the genes for progranulin (*GRN*), tau (*MAPT*), and *C9orf72*.^[@bibr8-0300060519860951][@bibr9-0300060519860951][@bibr10-0300060519860951][@bibr11-0300060519860951]--[@bibr12-0300060519860951]^

A major challenge for early and correct treatment and for development of novel therapies in FTD is accurate diagnosis because its symptoms overlap with those of Alzheimer's disease (AD). FTD is often associated with changes in personality, motivation, social behavior, and organizational abilities. "AD is characterized by a progressive amnestic disorder with episodic and semantic memory deficit", followed by a decline in other attentional, perceptual, and visuospatial abilities. In bvFTD, neuropsychiatric changes are the most prominent symptoms and usually precede or hide cognitive deficits. AD appears initially with cognitive deficits in the episodic memory domain and only later clinically manifests with alterations in social conduct, personality changes, and aphasia. However, non-cognitive disorders may sometimes characterize the onset of AD, making differential diagnosis a challenging task.^[@bibr13-0300060519860951]^

Neuropathological diagnosis of AD, which is defined by the presence at autopsy of both amyloid-ß plaques and tau neurofibrillary tangles, has been found in up to 30% of clinically diagnosed FTD cases.^[@bibr14-0300060519860951][@bibr15-0300060519860951][@bibr16-0300060519860951]--[@bibr17-0300060519860951]^ A high proportion of FTD syndromes are associated with AD pathology,^[@bibr18-0300060519860951]^ including 7% with bvFTD, 44% with naPPA, and 10% with svPPA. A recent study showed that 39.5% of a group of patients diagnosed with PPA were characterized by an AD-underlying pathology (22.2%, 35.7%, and 75% with naPPA, svPPA, and logopenic progressive aphasia, respectively).^[@bibr19-0300060519860951]^ Therefore, differentiation of AD from FTD spectrum disorders poses a serious diagnostic problem for clinicians.

Cerebrospinal fluid (CSF) biomarkers have the potential to optimize diagnostic accuracy and detect AD in the early phases when it could be possible to administer a potentially effective treatment. CSF values of major constituents of AD pathology, amyloid-ß 42 (Aß42), and total and phosphorylated tau (t-tau and p-tau), have been widely studied. These are associated with key features of AD, such as Aß42 for amyloid plaque load, t-tau for neuronal degeneration, and p-tau for neurofibrillary tangles.^[@bibr20-0300060519860951],[@bibr21-0300060519860951]^ A CSF profile characterized by low Aß42 levels and high concentrations of t-tau and p-tau accurately discriminates patients with AD from healthy older individuals, but, it is not equally useful in differential diagnosis of other dementias.^[@bibr22-0300060519860951][@bibr23-0300060519860951][@bibr24-0300060519860951]--[@bibr25-0300060519860951]^ Many studies have analyzed CSF biomarkers to verify possible diagnostic applications to distinguish FTD from AD and control subjects, but values of specificity and sensitivity are insufficient for diagnostic application.^[@bibr26-0300060519860951][@bibr27-0300060519860951][@bibr28-0300060519860951][@bibr29-0300060519860951][@bibr30-0300060519860951]--[@bibr31-0300060519860951]^ Interestingly, the most promising approach appears to be use of a biomarker ratio, rather than single measurements.^[@bibr32-0300060519860951][@bibr33-0300060519860951][@bibr34-0300060519860951][@bibr35-0300060519860951][@bibr36-0300060519860951]--[@bibr37-0300060519860951]^

This study aimed to compare cognitive and biomarker characteristics of patients with FTD, those with AD, and non-demented (ND) patients, and to determine the best CSF biomarker setting in distinguishing FTD (bvFTD and PPA) from AD cases.

Materials and methods {#sec2-0300060519860951}
=====================

Study population {#sec3-0300060519860951}
----------------

The study population consisted of 96 patients who were recruited at the INRCA Hospital, Neurology Unit, Ancona, Italy. Participants underwent a comprehensive clinical investigation that included medical history, neuropsychological and functional evaluation, neuroimaging, and laboratory tests. All subjects were administered the Mini-Mental State Examination (MMSE) according to standard procedures.^[@bibr38-0300060519860951],[@bibr39-0300060519860951]^ MMSE scores were calculated by grouping various items of the MMSE by domain: temporal orientation (0--5 points), spatial orientation (0--5 points), short-term memory (0--3 points), attention (0--5 points), verbal episodic memory (0--3 points), language (0--8 points), and visuospatial function (0 or 1 point). Brain atrophy was estimated on magnetic resonance imaging (MRI) scans using a modified version of the Pasquier scale,^[@bibr40-0300060519860951]^ where the final score was the mean of the values collected throughout the cerebrum. The score ranged from 0 to 3 as follows: 0 = no cortical atrophy, 1 = mild atrophy (opening of sulci), 2 = moderate atrophy (volume loss of gyri), and 3 = severe atrophy ("knife blade" atrophy); a value of 2 was considered pathological. Only patients with a score ≤2 were included in the study.

The work-up findings allowed participants to be divided into three groups as follows: patients with probable AD (n = 55), patients with FTD (n = 21), and ND patients (n = 20). The diagnosis had to be confirmed after at least a 2-year follow-up. Probable AD was diagnosed according to joint Alzheimer's Association Workgroup and National Institute of Aging guidelines.^[@bibr41-0300060519860951],[@bibr42-0300060519860951]^ FTD was diagnosed by current European Federation of Neurological Sciences-European Neurological Society guidelines of disorders associated with dementia, which included a revision on dementia syndromes outside of AD.^[@bibr43-0300060519860951],[@bibr44-0300060519860951]^ bvFTD and various forms of PPA were diagnosed according to specific established criteria.^[@bibr2-0300060519860951],[@bibr45-0300060519860951],[@bibr46-0300060519860951]^ Twelve patients in the FTD group predominantly had bvFTD, whereas nine patients predominantly had the PPA phenotype. The ND group consisted of individuals with peripheral nervous system disorders caused by trauma, degeneration, or other conditions. Exclusion criteria were age \<60 years, family history of disease, cerebrovascular accidents, anamnesis of delirium, cognitive decline induced by head injury, recently diagnosed or untreated thyroid disease, vitamin B12 or folic acid deficiency, intoxication with drugs or medications, severe depression (pseudodementia), chromosome 21 trisomy (Down syndrome), neurosyphilis, and human immunodeficiency virus dementia. The study was conducted according to the principles of the Declaration of Helsinki and was approved by the local ethics committee (Comitato Etico Regionale Marche \[CERM\] 2016 0259; 15 December 2016). Patients who participated in this study did not provide written or verbal informed consent because the study was a non-genetic, retrospective, observational study, and as such, did not require informed consent.

CSF sampling and assays {#sec4-0300060519860951}
-----------------------

CSF was obtained by lumbar puncture in the L3/L4 or L4/L5 intervertebral space. CSF samples were collected in polypropylene vials and delivered to the laboratory within 3 hours. Part of the sample was used for routine clinical laboratory analyses, including total cell count and total protein determination. A volume of 2 to 3 mL was centrifuged at 2000 × g for 10 minutes to pellet residual cells and other insoluble material. The supernatant was then aliquoted into polypropylene tubes and stored at −80°C until use for biomarker determination. CSF levels of Aß42, t-tau, and p-tau were determined using commercially available ELISA kits (Fujirebio Inc., Tokyo, Japan) according to the manufacturer's instructions. Assay performance was monitored using internal and external quality control samples. All analyses were performed by the same investigators who were blinded to patients' demographic, clinical, and cognitive data. The t-tau/Aß42 and p-tau/Aß42 ratios, which were derived from biomarker measurements, were also calculated. All of the subjects signed informed consent for lumbar puncture and analysis of CSF.

Statistical analysis {#sec5-0300060519860951}
--------------------

All variables were checked for normality by the Kolmogorov--Smirnov test. The characteristics of participants included in each group (AD, FTD, and ND) were compared using ANOVA for normally distributed variables, followed by Bonferroni's post-hoc analysis. The Kruskal--Wallis test and Mann--Whitney test were used for non-normally distributed variables. χ^2^ analysis was applied to compare dichotomous variables.

Linear regression was performed separately for each patient group to analyze relations between CSF biomarkers and MMSE scores. CSF biomarker concentrations and ratios were independent variables, MMSE and domain scores were dependent variables, and age and sex were covariates. Bonferroni correction for multiple comparisons was applied.

Receiver operating characteristics (ROC) curve analysis was performed to evaluate the discriminating power of CSF biomarkers in clinical diagnosis of AD and FTD. The area under the curve (AUC) was used as a measure of the overall performance of each ROC curve (with a 95% confidence interval), and optimal cutoff points of biomarkers were calculated by selecting the point on the ROC curve that maximized both sensitivity and specificity. Statistical significance was set at *p* \< 0.05. All analyses were performed using IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA).

Results {#sec6-0300060519860951}
=======

Comparative assessment of the patient groups {#sec7-0300060519860951}
--------------------------------------------

The demographic, clinical, and cognitive characteristics of the patient population are shown in [Table 1](#table1-0300060519860951){ref-type="table"}. The mean age in the FTD group was significantly lower than that in the AD group (*p* \< 0.05), whereas the sex distribution was almost identical among the groups. Assessment of MRI scans showed a significantly higher percentage of patients with brain atrophy in patients with AD and FTD compared with ND patients (both *p* \< 0.05). The MMSE total score, as well as verbal episodic memory, were significantly different among the three groups (all *p* \< 0.05). The AD group showed the lowest scores and the ND group showed the highest scores. However, visuospatial function and short-term memory scores were essentially the same among the three groups. Attention domain scores were significantly lower in the AD and FTD groups compared with the ND group (both *p* \< 0.05). Language and spatial orientation scores were significantly lower in the AD group compared with the ND group (both *p* \< 0.05). Finally, the temporal orientation domain was significantly impaired in patients with AD compared with those in the other two groups (both *p* \< 0.05).

###### 

Demographic, clinical, and cognitive characteristics of the patient groups.

![](10.1177_0300060519860951-table1)

                                          AD (n = 55)       FTD (n = 21)    ND (n = 20)
  --------------------------------------- ----------------- --------------- -------------
  Age (years)                             77.3 (7.1)^a^     72.0 (5.8)      72.8 (8.2)
  Sex (female)                            32 (58.2)         12 (57.1)       8 (40.0)
  Cerebral atrophy (pathological score)   42 (76.4)^b^      11 (52.4)^c^    3 (15.0)
  MMSE                                    14.5 (6.1)^a,b^   19.0 (6.2)^c^   28.1 (1.4)
  Temporal orientation                    1.9 (1.4)^a,b^    3.4 (1.7)       5.0 (0.0)
  Spatial orientation                     2.8 (1.6)^b^      3.9 (1.4)       5.0 (0.0)
  Short-term memory                       2.7 (0.8)         2.6 (0.9)       3.0 (0.0)
  Attention                               2.0 (1.6)^b^      2.5 (1.9)^c^    5.0 (0.0)
  Verbal episodic memory                  0.2 (0.5)^a,b^    1.1 (0.9)^c^    2.4 (0.5)
  Language                                5.4 (1.7)^b^      5.7 (2.0)       7.6 (0.5)
  Visuospatial function                   0.2 (0.4)         0.4 (0.5)       0.6 (0.5)

Data are presented as mean (standard deviation) of continuous variables and as number (%) of dichotomous variables (sex and cerebral atrophy). ANOVA, followed by Bonferroni's post-hoc analysis, was used to compare continuous variables. The χ^2^ test was applied to evaluate differences in percentages. ^a^*p* \< 0.05, AD versus FTD; ^b^*p* \< 0.05, AD versus ND; ^c^*p* \< 0.05, FTD versus ND. AD: Alzheimer's disease; FTD: frontotemporal dementia; ND: non-demented; MMSE: Mini-Mental State Examination.

CSF clinical laboratory data and biomarker values are reported in [Table 2](#table2-0300060519860951){ref-type="table"}. These data were not normally distributed. Therefore, we applied the Kruskal--Wallis test to compare the groups. None of the clinical laboratory parameters were significantly different among the three groups. However, concentrations and ratios of biomarkers showed differences among the groups. Aß42 concentrations were significantly lower, and t-tau/Aß42 and p-tau/Aß42 ratios were higher in the AD group compared with the other two groups (all *p* \< 0.05). Two other indices, t-tau and p-tau concentrations, were significantly higher in the AD and FTD groups compared with the ND group (all *p* \< 0.05). Biomarker values of patients with bvFTD and PPA are reported in [Table 3](#table3-0300060519860951){ref-type="table"}. There were no significant differences in CSF biomarker values between the two groups of patients.

###### 

CSF clinical laboratory data and biomarker values.

![](10.1177_0300060519860951-table2)

                                 AD (n = 55)          FTD (n = 21)       ND (n = 20)
  ------------------------------ -------------------- ------------------ ---------------
  CSF total protein (mg/dL)      39.6 (18.8)          37.9 (16.7)        40.4 (21.9)
  CSF cell count (cells/mm^3^)   0.0 (3.5)            2.0 (5.0)          0.0 (2.8)
  CSF chloride (mEq/L)           124.5 (7.0)          124.0 (8.5)        127.0 (6.8)
  CSF albumin (mg/dL)            23.8 (18.5)          24.4 (12.3)        24.7 (17.2)
  CSF immunoglobulin G (mg/dL)   2.8 (2.1)            2.7 (1.7)          3.5 (3.1)
  Aß42 (pg/mL)                   381.1 (198.6)^a,b^   713.3 (378.5)      689.5 (410.7)
  t-tau (pg/mL)                  449.8 (483.5)^b^     308.0 (263.8)^c^   167.5 (141.7)
  p-tau (pg/mL)                  65.0 (45.0)^b^       51.8 (30.6)^c^     43.4 (25.5)
  t-tau/Aß42                     1.2 (1.4)^a,b^       0.5 (0.6)^c^       0.2 (0.1)
  p-tau/Aß42                     0.2 (0.1)^a,b^       0.1 (0.1)          0.1 (0.0)

Data are presented as median (interquartile range). The Kruskal--Wallis test was used to compare the groups. ^a^*p* \< 0.05, AD versus FTD; ^b^*p* \< 0.05, AD versus ND; ^c^*p* \< 0.05, FTD versus ND. AD: Alzheimer's disease; FTD: frontotemporal dementia; ND: non-demented; CSF: cerebrospinal fluid; Aß42: amyloid-ß 42; t-tau: total tau; p-tau; phosphorylated tau.

###### 

CSF biomarker values of patients with bvFTD and PPA.

![](10.1177_0300060519860951-table3)

                  bvFTD (n = 12)   PPA (n = 9)     *p* value
  --------------- ---------------- --------------- -----------
  Aß42 (pg/mL)    522.0 (327.7)    811.7 (156.9)   0.075
  t-tau (pg/mL)   351.6 (183.8)    268.1 (257.2)   0.829
  p-tau (pg/ml)   58.8 (25.3)      44.9 (27.9)     0.122
  t-tau/Aß42      0.48 (0.52)      0.36 (0.29)     0.515
  p-tau/Aß42      0.10 (0.09)      0.06 (0.04)     0.055

Data are presented as median (interquartile range). The Mann--Whitney test was used to compare the groups. CSF: cerebrospinal fluid; bvFTD: behavioral variant frontotemporal dementia; PPA: primary progressive aphasia; Aß42: amyloid-ß 42; t-tau: total tau; p-tau; phosphorylated tau.

Relations between the cognitive profile and CSF biomarkers {#sec8-0300060519860951}
----------------------------------------------------------

Linear regression analyses were performed to evaluate if variations in specific cognitive domains, as measured by MMSE scores, were correlated with values of CSF biomarkers. The AD and ND groups failed to show significant associations for any of the CSF biomarkers, whereas a significant relationship was obtained in patients with FTD. In patients with FTD, poor temporal orientation scores were associated with low Aß42 levels after correction for age and sex (R^2^ = 0.520; *p* = 0.028).

ROC curve analyses {#sec9-0300060519860951}
------------------

When ROC analyses were performed for each biomarker and ratio, only p-tau/Aß42 and t-tau/Aß42 ratios were able to significantly differentiate AD from FTD ([Figure 1](#fig1-0300060519860951){ref-type="fig"}). The AUC was 0.761 for p-tau/Aß42 (*p =* 0.001). Using a cutoff value of 0.0098, the CSF p-tau/Aß42 ratio had a sensitivity of 85.5% and a specificity of 61.1% for distinguishing FTD from AD. The AUC was 0.780 for t-tau/Aß42 (*p* \< 0.001). Using a cutoff value of 0.565, the CSF t-tau/Aß42 ratio had a sensitivity of 83.6% and specificity of 66.7% for distinguishing FTD from AD. These two ratios were also applied in distinguishing AD from bvFTD and AD from PPA separately ([Table 4](#table4-0300060519860951){ref-type="table"}). Both of these ratios were better at differentiating AD from PPA than for differentiating AD from bvFTD. The p-tau/Aß42 ratio showed acceptable values of sensitivity (92.7%) and specificity (75.0%) in distinguishing AD from PPA. According to a consensus report, a useful diagnostic biomarker should have sensitivity and specificity approaching or exceeding 80%.^[@bibr47-0300060519860951]^ Therefore, the p-tau/Aß42 ratio appears to fulfill these requirements in differentiating AD from PPA.

![ROC curve analysis of p-tau/Aß42 and t-tau/Aß42 for discriminating AD from FTD. (a) ROC curve of p-tau/Aß42. The ratio distinguished patients with AD from those with FTD with a sensitivity of 85.5% and a specificity of 61.1% using a cutoff value of 0.0098. (b) ROC curve of t-tau/Aß42. The ratio distinguished patients with AD from those with FTD with a sensitivity of 83.6% and a specificity of 66.7% using a cutoff value of 0.565. ROC: receiver operating characteristics; Aß42: amyloid-ß 42; p-tau; phosphorylated tau; t-tau: total tau; AD: Alzheimer's disease; FTD: frontotemporal dementia.](10.1177_0300060519860951-fig1){#fig1-0300060519860951}

###### 

ROC analyses for discriminating AD from bvFTD and PPA.

![](10.1177_0300060519860951-table4)

                     Cutoff   Sensitivity (%)   Specificity (%)   Area under the curve (95% CI)   *p*
  ------------------ -------- ----------------- ----------------- ------------------------------- -------
  p-tau/Aß42                                                                                      
   AD versus bvFTD   0.162    61.8              80.0              0.695                           0.052
   AD versus PPA     0.073    92.7              75.0              0.843                           0.002
  t-tau/Aß42                                                                                      
   AD versus bvFTD   0.504    87.3              60.0              0.749                           0.013
   AD versus PPA     0.738    70.9              87.5              0.818                           0.004

ROC: receiver operating characteristics; AD: Alzheimer's disease; bvFTD: behavioral variant frontotemporal dementia; PPA: primary progressive aphasia; CI: confidence interval; Aß42: amyloid-ß 42; t-tau: total tau; p-tau; phosphorylated tau.

Discussion {#sec10-0300060519860951}
==========

This study examined CSF biomarkers and cognitive status in a population of patients with AD, FTD, or no dementia. We found that these three patient groups showed numerous differences regarding cognitive domain scores, and Aß42, t-tau, and p-tau levels. Additionally, we found that low Aß42 levels were associated with a worse performance in the temporal orientation domain only in the FTD group. Analysis of CSF biomarkers for differential diagnosis of FTD and AD showed that only the p-tau/Aß42 ratio reached sufficient levels of sensitivity and specificity to discriminate AD from PPA. None of the CSF biomarkers were adequate for distinguishing AD from bvFTD, or for distinguishing AD from FTD considered as a whole group.

Cognitive evaluation results indicated that distinct domain scores were different among the groups. Patients with AD showed greater deficits on tests of verbal episodic memory and temporal orientation than did those with FTD and ND. These findings are consistent with clinical observations that AD predominantly affects memory and orientation functioning, while language, executive skills, and attention are more likely to be impaired in FTD. Nevertheless, we did not find lower scores in these domains in the FTD group. Additionally, MMSE score analysis showed significant differences between AD and ND in five domains, while differences between FTD and ND were found only in three domains. Our results confirm previous observations on the limited usefulness of the MMSE in evaluating patients with FTD.^[@bibr48-0300060519860951]^ People with AD are expected to perform worse than people with FTD with a comparable stage of dementia. This is because the cognitive domains that are assessed by the MMSE are those most prominently affected in AD. Even the Montreal Cognitive Assessment, with its added executive function items, is significantly worse in those with AD compared with those with FTD.^[@bibr49-0300060519860951]^ Other global cognitive tests, such as the Addenbrooke's Cognitive Examination test and its subsequent versions, or specific tests for frontal executive function (e.g., Frontal Assessment Battery, Trail Making Test, and Weigl Color Form Sorting Test) could be more informative.

CSF analysis in the present study showed that Aß42 was a biomarker for AD, while t-tau and p-tau were effective for distinguishing AD and FTD from ND, which is in line with the role of tau proteins in neurodegeneration. Although lower CSF Aß42 levels in AD compared with FTD and controls have been reported by many investigators, there is more variability with regard to t-tau and p-tau among groups.^[@bibr26-0300060519860951],[@bibr27-0300060519860951],[@bibr35-0300060519860951],[@bibr50-0300060519860951]^ The main reasons for these inconsistencies are the potential presence of mixed pathologies in patients with dementia, a significant degree of underlying AD pathology in healthy older people, and variability in CSF measurements.^[@bibr30-0300060519860951]^

When analyzing the relations between MMSE domain scores and CSF biomarkers among the three groups, we found only one significant association in the FTD group of temporal orientation domain scores and Aß42 levels. The lower the temporal orientation domain score was, the lower Aß42 levels were. Impaired orientation as measured by the MMSE is a specific deficit, it is not due to diffuse cognitive dysfunction, and it is likely to be associated with changes in specific neural substrates, such as the hippocampus and parietal cortex.^[@bibr51-0300060519860951],[@bibr52-0300060519860951]^ Our findings suggest a possible association between a higher degree of AD pathology and a profile of more temporal orientation disabilities on cognitive tests in FTD. Animal models and *in vitro* studies have shown that Aß, tau, and α-synuclein mutually promote their accumulation, thus providing a partial explanation for the simultaneous presence of different neuropathological features in the same subject.^[@bibr53-0300060519860951],[@bibr54-0300060519860951]^ This also suggests the possibility of onset, during aging, of different pathogenic processes in multiple brain regions that eventually enhance their respective development in a synergic way. Therefore, the phenomenon of AD neuropathology could be a comorbidity in several dementia syndromes, including FTD, indicating that "pure" etiologies are relatively rare.

The lack of a relationship between CSF biomarker levels and MMSE scores in patients with AD supports the view that different degrees of cognitive impairment in AD are not reflected in Aß42, t-tau, and p-tau levels. According to the accepted temporal trend of CSF biomarkers in AD, they reach a peak in the preclinical stage of the disease and plateau after diagnosis, and show no further changes with worsening of the clinical condition.^[@bibr55-0300060519860951]^ The lack of a relationship between CSF biomarker levels and MMSE scores in the ND group deserves some discussion. Associations between amyloid burden and specific cognitive domains, and between tau values and visuospatial episodic memory have been described in cognitively healthy individuals.^[@bibr56-0300060519860951],[@bibr57-0300060519860951]^ However, a number of methodological differences, such as group composition, sensitivity of the cognition measures used, and sample size, prevent comparison of the results of such studies with our data. Additionally, our sample was unlikely to have included a significant number of individuals with preclinical AD. Therefore, a relationship between biomarkers and cognitive abilities was unlikely to emerge.

We tested CSF biomarkers levels and ratios to evaluate the usefulness of CSF biomarkers in differential diagnosis of FTD and AD in our clinically defined cases. We found that the p-tau/Aß42 ratio was a sensitive and specific biomarker for discriminating PPA, which is the FTD form with primary language disturbance, from AD. Other reports showed that the combination of p-tau and Aß42 could be considered useful in distinguishing FTD from AD. Schoonenboom and colleagues showed that the combined Aß42 and p-tau dosage allowed differentiation of patients with AD from those with FTD, with a sensitivity of 72% and a specificity of 93%.^[@bibr58-0300060519860951]^ More recently, De Souza et al.^[@bibr35-0300060519860951]^ reported high sensitivity and specificity of the p-tau/Aß42 ratio in differentiation of AD from bvFTD (sensitivity = 95% and specificity = 85.2) and from svPPA (sensitivity = 91.7% and specificity = 84.2). However, some reports have shown that t-tau/Aß42 is the best ratio for distinguishing AD and FTD.^[@bibr28-0300060519860951],[@bibr34-0300060519860951]^ Our study showed, by a rigorous statistical approach, the validity of the p-tau/Aß42 ratio in discriminating PPA, as a specific group, from AD. To the best of our knowledge, previous reports analyzed other diagnostic cohorts included in the FTD spectrum or they did not calculate the *p* value associated with ROC curve analysis.

Our study has some limitations. We did not have pathological confirmation of our diagnoses. To reduce this bias, we attempted to achieve the highest clinical accuracy by means of adopting strict clinical criteria and a clinical follow-up of 2 years. Use of the MMSE as the sole measure of cognition may have determined low sensitivity and accuracy in evaluating cognitive changes. However, temporal orientation and verbal episodic memory MMSE scores have been reported to correlate well with the Free and Cued Selective Reminding Test.^[@bibr59-0300060519860951]^ Moreover, the MMSE score is the only independent predictor for postoperative cognitive dysfunction in patients with severe systemic diseases.^[@bibr60-0300060519860951]^ Another limitation is that the small sample size could have limited the validity of our results. However, the sample size calculated for the present study was aimed at identifying marked differences among groups, whereas investigation of small differences would have required a larger number of subjects.

Regardless of these limitations, our findings suggest that FTD and AD have comparatively distinct CSF biomarker profiles. Patients with FTD are characterized by higher levels of CSF Aß42, and lower t-tau/Aß42 and p-tau/Aß42 values compared with patients with AD. The ratio of p-tau/Aß42 appears to be the most sensitive and specific biomarker for discriminating FTD with primary language disturbances from AD.

Conclusion {#sec11-0300060519860951}
==========

A major challenge for early and correct treatment of neurodegenerative disorders is an accurate diagnosis. In particular, differential diagnosis of AD and FTD may be a difficult task because of overlapping symptoms and a lack of specific biomarkers for FTD. Our study suggests that the p-tau/Aß42 ratio could be useful in differential diagnosis of AD and FTD with primary language disturbances. However, the p-tau/Aß42 ratio does not function well in distinguishing AD from behavioral variant FTD, or from FTD considered as a whole group. Exploratory analyses for novel biomarkers that have diagnostic utility in FTD are ongoing. Promising data are available concerning a possible diagnostic role of TAR DNA-binding protein 43, progranulin, and tau isoforms, but their definitive validation as diagnostic tools for the clinical setting is still lacking.
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